NUP214 and acute myeloid leukemia: Similarly, ALMA_3_BM (13–39 years, female; coverage 1.14x), diagnosed with AML FAB M2, t(6;9), showed accurate prediction as AML with t(6;9); DEK::NUP214, supported by genomic confirmation of the NUP214 rearrangement at ultra-low coverage (Fig. 6b).